Determination of Olmesartan Medoxomil In Bulk And Pharmaceutical Formulations By Validated RP-HPLC Method
DOI:
https://doi.org/10.61841/jb6ezz39Keywords:
Olmesartan medoxomil, Isocratic, HPLC, Trifluoro acetic acid, AcetonitrileAbstract
Analytical method was developed for the estimation of Olmesartan medoxomil drug substance by liquid chromatography. The chromatographic separation was achieved on Ascentris express C18 100*4.5um at ambient temperature. The separation was achieved by employing a mobile phase consisting of 0.1%v/v formic acid in water: Acetonitrile (50:50). The flow rate was 0.6 ml/ minute and UV detector was set at 230nm. The average retention time for Olmesartan medoxomil was found to be 1.9 min and the proposed method was validated for selectivity, precision, linearity and accuracy. All validation parameters were within the acceptable range. The assay methods were found to be linear in the range of 50-150µg/ml for Olmesartan medoxomil
Downloads
References
[1] Manoharan, R., et al. “Selection of Intermediate Routes for Secure Data Communication Systems Using Graph Theory Application and Grey Wolf Optimization Algorithm in MANETs.” IET Networks, 2020.
[2] Rajesh, M., & Gnanasekar, J. M. “Path Observation Based Physical Routing Protocol for Wireless Ad Hoc Networks.” Wireless Personal Communications, 97 (2017): 1267–1289. https://doi.org/10.1007/s11277-017-4565-9
[3] Rajesh, M. “Streamlining Radio Network Organizing Enlargement Towards Microcellular Frameworks.” Wireless Personal Communications, 2020. https://doi.org/10.1007/s11277-020-07336-9
[4] Hünseler, C., Paneitz, A., Friedrich, D., et al. “Angiotensin II Receptor Blocker Induced Fetopathy: 7 Cases.” Klin Padiatr, 223(1) (2011): 10–14.
[5] Ewald, S., Nickenig, G., & Böhm, M. “Olmebest-Study: Reduction of Blood Pressure in the Treatment of Patients with Mild-to-Moderate Essential Hypertension – Interim Analysis of the German Sub Study.” American Journal of Hypertension, 18 (2005): 2.
[6] Mason, R. P. “Vascular Health and Risk Management.” Dovepress, 2011; 7: 405–416.
[7] Brunner, H. R. “Clinical Efficacy and Tolerability of Olmesartan.” Clinical Therapeutics, 26(Suppl A) (2004): A28–A32.
[8] Rubio-Tapia, A., Herman, M. L., Ludvigsson, J. F., et al. “Severe Spruelike Enteropathy Associated with Olmesartan.” Mayo Clinic Proceedings, 87(8) (2012): 732–738.
[9] Chobanian, A. V., Bakris, G. L., Black, H. R., et al. “The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure.” JAMA, 289 (2003): 2560–2572.
[10] Brunner, H. R. “Experimental and Clinical Evidence That Angiotensin II Is an Independent Risk Factor for Cardiovascular Disease.” American Journal of Cardiology, 87 (2001): 3C–9C.
[11] Aulakh, G. K., Sodhi, R. K., & Singh, M. “An Update on Non-Peptide Angiotensin Receptor Antagonists and Related RAAS Modulators.” Life Sciences, 81(8) (2007): 615–639.
[12] Chrysant, S. G., Marbury, T. C., & Robinson, T. D. “Antihypertensive Efficacy and Safety of Olmesartan Medoxomil Compared with Amlodipine.” Journal of Human Hypertension, 17 (2003): 425–432.
[13] Fletcher, A. E., Palmer, A. J., & Bulpitt, C. J. “Cough with ACE Inhibitors: How Much of a Problem?” Journal of Hypertension Supplement, 12 (1994): S43–S47.
[14] Koike, H. “New Pharmacologic Aspects of CS-866, the Newest Angiotensin II Receptor Antagonist.” American Journal of Cardiology, 87(Suppl 8A) (2001): 33C–36C.
[15] Lewington, S., Clarke, R., Qizilbash, N., et al. “Age-Specific Relevance of Usual Blood Pressure to Vascular Mortality.” The Lancet, 360 (2002): 1903–1913.
[16] Murakami, T., Konno, H., & Fukutsu, N. “Identification of a Degradation Product in Stressed Tablets of Olmesartan Medoxomil.” Journal of Pharmaceutical and Biomedical Analysis, 2008: 1–7.
[17] Celebier, M., & Sacide, A. “Development of a CZE Method for the Determination of Olmesartan Medoxomil in Tablets.” Chromatographia, 66 (2007): 929–933.
[18] Liu, D., Hu, P., & Matsushima, N. “Quantitative Determination of Olmesartan in Human Plasma and Urine by LC–MS/MS.” Journal of Chromatography B, 856 (2007): 190–197.
[19] Shah, N. J., & Suhagia, B. N. “Simultaneous HPTLC Estimation of Olmesartan Medoxomil and Hydrochlorothiazide.” Indian Journal of Pharmaceutical Sciences, 69 (2007): 834–836.
[20] Celebier, M., & Altinoz, S. “Determination of Olmesartan Medoxomil by UV–Vis Spectrophotometry.” Pharmazie, 64 (2007): 419–422.
[21] Zarapkar, S., & Kanyawar, N. “Simultaneous Estimation of Amlodipine and Losartan Potassium by RP-HPLC.” Indian Drugs, 39 (2002): 338–341.
[22] Rane, V. P., Patil, K. R., Sangshetti, J. N., et al. “Stability Indicating LC Method for Determination of Olmesartan.” Chromatographia, 69(1) (2009): 169.
[23] Patel, C. V., Khandhar, A. P., Captain, A. D., & Patel, K. T. “Validated RP-HPLC Methods for Ramipril and Olmesartan.” Eurasian Journal of Analytical Chemistry, 2 (2007): 159.
[24] Chitlange, S. S., Bagri, K., & Sakarkar, D. M. “Stability Indicating RP-HPLC Method for Valsartan and Amlodipine.” Asian Journal of Research in Chemistry, 1(1) (2008): 15–18.
[25] Bari, P. D., & Rote, A. R. “RP-LC and HPTLC Methods for Determination of Olmesartan and Hydrochlorothiazide.” Chromatographia, 69 (2009): 1469–1472.
[26] Chitlange, S. S., Mohammed, I., & Sakarkar, D. M. “RP-HPLC Method for Amlodipine and Metoprolol.” Asian Journal of Pharmaceutics, 2(4) (2008): 232–234.
[27] Hamrapurkar, P. D., & Gadapayale, K. K. “RP-HPLC Stability Indicating Method for Olmesartan Medoxomil.” International Journal of Applied Science and Engineering, 11(2) (2013): 137–147.
[28] Zhao, Z., Wang, Q., Tsai, E. W., Qin, X. Z., & Ip, D. “Identification of Losartan Degradates.” Journal of Pharmaceutical and Biomedical Analysis, 20 (1999): 129–136.
[29] Rane, V. P., Patil, K. R., Sangshetti, J. N., Yeole, R. D., & Shinde, D. B. “Stability-Indicating LC Method for the Determination of Olmesartan.” Chromatography, 69 (2009): 169–173.
[30] Vaidya, V. V., Roy, S. M. N., Yetal, S. M., Joshi, S. S., & Parekh, S. A. “LC-MS/MS Determination of Olmesartan in Human Plasma.” Journal of Mass Chromatography, 67: 147–150.
[31] ICH. “Validation of Analytical Procedures: Definitions and Terminology.” Geneva (1996).
[32] U.S. FDA. 21 CFR 211 – Current Good Manufacturing Practice for Finished Pharmaceuticals.
[33] U.S. FDA. Analytical Procedures and Method Validation: CMC Documentation. Draft Guidance (2000).
[34] ISO/IEC 17025. “General Requirements for Testing and Calibration Laboratories.” (2005).
[35] ICH. “Validation of Analytical Procedures: Methodology.” Geneva (1996).
[36] U.S. EPA. “Guidance for Methods Development and Validation for RCRA Program.” (1995).
[37] USP 30–NF 25. “Validation of Compendial Methods.” General Chapter 1225 (2007).
[38] U.S. FDA. “Bioanalytical Method Validation.” Guidance for Industry.
[39] Hokanson, G. C. “Life Cycle Approach to Analytical Method Validation.” Pharmaceutical Technology, Sept. 1994: 118–130.
[40] ICH. “Q2A: Text on Validation of Analytical Procedures.” Fed. Register, 60(40): 11260–11262 (1995).
[41] ICH. “Q2B: Validation of Analytical Procedures: Methodology.” Fed. Register, 62(96): 27463–27467 (1997).
[42] FDA. “Analytical Procedures and Methods Validation: CMC Documentation.” Fed. Register, 65(169): 52776–52777 (2000).
[43] FDA Guidance. Available at: www.fda.gov/cder/guidance/cmc3.pdf
[44] USP 25–NF 20. “Validation of Compendial Methods, Section 1225.” Rockville, USA (2002): 2256.
[45] International Journal of Psychosocial Rehabilitation, Vol. 24, Issue 10, 2020. (Received, Revised, Accepted details).
Downloads
Published
Issue
Section
License
This work is licensed under a Creative Commons Attribution 4.0 International License.
You are free to:
- Share — copy and redistribute the material in any medium or format for any purpose, even commercially.
- Adapt — remix, transform, and build upon the material for any purpose, even commercially.
- The licensor cannot revoke these freedoms as long as you follow the license terms.
Under the following terms:
- Attribution — You must give appropriate credit , provide a link to the license, and indicate if changes were made . You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
- No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
Notices:
You do not have to comply with the license for elements of the material in the public domain or where your use is permitted by an applicable exception or limitation .
No warranties are given. The license may not give you all of the permissions necessary for your intended use. For example, other rights such as publicity, privacy, or moral rights may limit how you use the material.
